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PER OMVIK, ROBERT C. TARAZI, and EMMANUEL L. Bivo
Research Division, The Cleveland Clinic Foundation, Cleveland, Ohio
Determination of extracellular fluid volume in uremic patients
by oral administration of radiosulfate. Determinations of extra-
cellular fluid volume (ECF) are needed both for understanding
and management of problems in patients with hypertension and
chronic renal disease. Because of difficulties with i.v. radio-
isotope markers, accuracy of oral radiosulfate (100 MCi) was as-
sessed in four groups of subjects. In all, radiosulfate space corre-
lated with expected value for weight, but equilibration time and
decay rate of plasma levels was significantly more rapid in nor-
mal volunteers than it was in chronic renal failure (94 8vs. 161
16 mm and 14.6 0.9 vs. 0.5 0.l%/hr, respectively; P <
0.001). Repeated determinations in hypertensive patients main-
tained on constant sodium intake varied by 2.6 1.1%. More-
over, oral radiosulfate was sensitive enough to detect changes
induced by either hemofiltration (14 patients) or saline infusion (4
patients); variations in body weight and radiosulfate space corre-
lated closely (r = 0.99) with a slope of 1.03. Thus, this method
can provide reproducible and accurate measure of ECF changes
in subjects with either normal or impaired renal function. Clinical
value was demonstrated by finding fluid overload (radiosulfate
space, 25 1.1% of body wt vs. 18.9 0.7% for normal) in
absence of clinical signs of fluid retention in 11 out of 18 patients
on regular hemodialysis.
Determination du volume extracellulaire chez les malades
urémiques par l'administration orale de radiosulfate. Les deter-
minations du volume extracellulaire (ECF) sont nécessaires a Ia
fois a Ia comprehension et au traitement des problèmes surve-
nant chez les malades atteints d'hypertension et d'insuffisance
rénale chronique. A cause des difficultés liées a l'emploi par voie
iv. de rnarqueurs radioisotopiques la precision de l'utilisation
du radiosulfate (100 .tCi) par voie orale a été évaluée dans quatre
groupes de sujets. Chez tous l'espace radiosulfate est correlé
avec Ia valeur attendue en fonction du poids mais le temps
d'équilibration et la diminution de Ia concentration plasmatique
sont plus rapides chez les volontaires normaux que chez les su-
jets atteints d'insuffisance rénale chronique (94 8 et 161 16
mm; 14,6 0.9 et 0,5 0,1%/hr, respectivement, P < 0,001).
Des determinations itératives chez les malades hypertendus
maintenus a un apport de sodium constant varient de 2,6 1,1%.
De plus, le radiosulfate par voie orale permet une sensibilité suf-
fisante pour déceler les modifications liées soit a l'hémofiltration
(14 malades) ou a l'administration de sodium chloride isotonique
(4 malades). Les variations du poids corporel et de l'espace ra-
diosulfate sont étroitement correlées (r = 0,99) avec une pente
de 1,03. Ainsi cette méthode peut-elle permettre des deter-
minations precises et reproductibles des modifications de ECF
chez des sujets dont la fonction rénale est anormale ou diminuée.
L'intérêt clinique a été démontré par la constatation d'une sur-
charge liquidienne (espace radiosulfate a 25 1,1% du poids cor-
porel au lieu de 18,9 0,7%, valeur norinale) en l'absence de
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symptômes cliniques de retention liquidienne chez 11 parmi 18
malades en hémodialyse chronique.
Fluid overloading is a threat to uremic patients on
chronic hemodialysis. The development of more ef-
ficient techniques [1, 2] to deal with this problem
requires for their optimal use more precise determi-
nation of fluid balance than is possible from clinical
signs alone. It is well known that considerable
amounts of fluid might be retained before signs of
overloading appear. Hence, patients on hemo-
dialysis might be chronically overhydrated; the
many variables involved, however, make measure-
ments of body weight difficult to interpret. Further,
since the distribution of extracellular fluid (ECF)
between its intravascular and interstitial com-
partments may be altered in renal hypertension [3-
5], investigations of hemodynamic alterations will
depend again on accurate ECF determinations.
Unfortunately, injectable radioisotopes, used as
tracers for measurements of ECF, have become
practically unavailable. Because of this, Bauer [6]
recently has investigated in normal man the possi-
bility of using radiosulfate administered by mouth,
as an alternative to i.v. injection. The distribution
volume of radiosulfate has been considered to be
close to ECF [7], and the isotope previously has
been applied i.v. for measurements of ECF both in
normal subjects [8-13] and in patients with chronic
renal failure [14—161. Therefore, the aim of the pres-
ent study was to evaluate the oral radiosulfate tech-
nique for determination of ECF in uremic patients.
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Accuracy of the technique was tested in uremic
patients by repeated measurements before and after
acute volume depletion of hemofiltration and fol-
lowing volume loading by saline infusion. Repro-
ducibility was examined by repeated determina-
tions in a group of hypertensive patients on a con-
stant sodium diet; the normal range of radiosulfate
space was determined in a group of normal volun-
teers.
Methods
Patient population. Radiosulfate space was mea-
sured after oral administration of 100 /LCi of radio-
sulfate in four groups of subjects: one of normal vol-
unteers and three groups of patients. None of the
latter presented any clinical or radiology evidence
of fluid retention, pulmonary congestion, or cardiac
decompensation; after saline infusion, only two of
the four patients who had expansion studies devel-
oped increased stiffness of the fingers and a slight
swelling of their faces. The study was approved in-
dependently by both the Isotope and the Institution-
al Review Committees of the Cleveland Clinic
Foundation, and all patients gave their informed
consent to the procedures. Age, sex, and renal dis-
ease of each patient is listed in Table 1.
Group 1 consisted of 12 volunteers of both sexes
without renal or cardiovascular diseases. In group 2
(seven hypertensive patients), reproducibility was
tested by repeated measurements at 2- to 6-day in-
tervals under conditions of monitored constant so-
dium intake (100 mEq/day). Group 3 consisted of
four uremic patients treated with regular hemo-
dialysis for 5 hours, 3 days/week. Measurements
were performed on the day after hemodialysis and
were repeated 1 to 3 days later following volume
expansion with isotonic saline (0.9% sodium chlo-
ride) infusion. In two of these patients, volume ex-
pansion was continued for another 2 days; measure-
ments were once more repeated at the end of the
second volume expansion period. In group 4, con-
sisting of 14 uremic patients, hemofiltration was
substituted for one session of regular hemodialysis,
and radiosulfate space was measured on the same
day before and after the filtration. The technique of
hemofiltration has been described elsewhere [1, 2].
It was performed by applying a negative pressure of
100 to 250 mm Hg to a Travenol artificial kidney
without dialysis fluid. Blood flow through the Tray-
enol kidney was kept at 150 to 200 mi/mm, and the
transmembrane pressure was not to exceed 300 mm
Hg; under these conditions, hemofiltrate was re-
moved from patients at a rate ranging between 500
and 1,000 ml/hour for 2 to 3 hours. The amount of
hemofiltration fluid was measured directly in a mea-
suring cylinder, and the patients were weighed be-
fore and after the procedure.
ECF determination. Food and water were with-
held from the evening before and until the end of the
determination. Radiosulfate (100 Ci of Na2 35S04,
New England Nuclear, Boston, Mass.) was with-
drawn from a stock solution containing 100 j.tCi/ml
by a disposable 1-ml insulin syringe, and it was
mixed in a glass of water (approximately 75 ml).
The radiosulfate was administered by mouth at 8
A.M. to subjects of groups 1 and 2 and to eight of the






m1124 hr Kidney disease
1 M 20 2 0 Chronic glomerulonephritis
2 F 49 2 0 Chronic glomerulonephritis
3 F 69 2 25 Chronic glomerulonephritis
4 F 20 2 470 Chronic glomerulonephritis
5 M 53 0 0 Chronic glomerulonephritis
6 M 47 2 300 Chronic glomerulonephritis
7 M 28 0 0 Chronic glomerulonephritis
8 M 28 2 670 Chronic pyelonephritis
9 F 31 0 0 Chronic pyelonephritis
10 M 60 2 25 Nephrosclerosis
11 M 69 2 0 Nephrosclerosis
12 M 39 2 190 Nephrosclerosis
13 M 56 2 400 Nephrosclerosis
14 M 53 2 800 Diabetic nephropathy
IS M 66 2 600 Diabetic nephropathy
16 F 56 2 100 Polycystic disease of the kidney
17 M 54 2 0 Bilateral renal arterial stenosis
18 M 53 2 90 Nephrotic syndrome
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uremic patients (groups 3 and 4), but to the remain-
ing ten patients of groups 3 and 4, the isotope was
given at 9 P.M. the evening before the study. No
attempt was made to determine the residue in the
glass since this would not account for other possible
errors, for example, loss of isotope during prepara-
tion of the dose or trapping of some of the isotope in
the oropharyngeal cavity. Blood samples were
drawn at intervals ranging from .50 to 8 hours for a
period of 4 to 50 hours after administering the iso-
tope; in subjects with normal renal function, it was
found most practical to collect four blood samples
at 1.5, 2.5, 3.5, and 4.5 hours after the isotope had
been administered. Plasma was obtained by centri-
fuging the samples at 2,000 rpm for 10 mm. In the
subjects of group 4, three blood samples were
drawn at 5-mm intervals before and after hemo-
filtration. From four uremic patients with remnant
urine excretion and five normal volunteers, urine
was collected in 18 clearance periods for 4 to 36
hours after administration of radiosulfate.
One-milliliter samples of plasma, urine, and he-
mofiltration fluid were prepared for counting by pre-
cipitation of proteins with 0.1 ml of 0.5 N perchioric
acid; duplicates of 0.3 ml of the supernatant were
mixed with 10 ml of scintillation fluid (Biofluor,
New England Nuclear, Boston, Mass.) and were
counted in a well scintillation counter with automat-
ic standardization (Packard Tri-Carb scintillation
spectrometer model 3330) for a minimum of 10,000
counts.
In the subjects with normal renal function (groups
1 and 2), sample counts were used to calculate the
theoretical zero time concentration of radiosulfate
by using the sum of the least square method as de-
scribed by Bauer [611. For uremic patients (groups 3
and 4), the long equilibration period introduced
some practical difficulty in determining the best
method for calculation. Initial observations in eight
patients indicated that plasma sulfate concentration
fell at a fairly constant rate of 0.5 0.1%/hr. To the
remaining ten patients, radio sulfate was therefore
administered the evening before the study, and
blood samples were collected in the morning. For
all patients, zero time concentrations were calcu-
lated by multiplying the sample counts with a cor-
rection factor of 0.5%/hr after drinking the radio-
sulfate.
The administered dose of radiosulfate (D) was
calculated from standards prepared in quadruples
from the stock solution, diluted to approximately
the same concentration as in plasma, and counted
under the same conditions. Radiosulfate space was
calculated from D and zero time concentration (C)
according to the formula:
—
Dcpm X W x kRadiosulfate space
Ccpmimi
(1)
where cpm is counts per minute; ml is milliliter; k is
a constant (0.2224) representing the multiple prod-
uct of the Gibbs-Donnan factor (0.9), the sample
size (0.3 ml), a correction (0.906) for the difference
in counting efficiency between standard solution
(84.6%) and 0.3 ml plasma samples (76.9%), and an-
other correction (0.909) for dilution of samples by
perchloric acid; and w is water content of serum
calculated from serum proteins according to Ohira,
Ito, and Ikawa [171. The fall in ECF during hemo-
filtration (zECF) was calculated as the difference
between radiosulfate space before and after hemo-
filtration (subscripts 1 and 2, respectively).
ECF= Dxw1xk (D-U)xw2xk
C1 C2 (2)
where U is loss of radiosulfate (in cpm) in hemo-
filtrate. Data are presented as means 1 SEM. The
statistical probability (P) of differences was calcu-
lated with Wilcoxon's test for two samples and for
paired comparison [181. The differences were re-
garded as significant at P < 0.05. Correlation coeffi-
cients were calculated by the method of least
squares, and comparison of regression lines a-
mong groups was made by analysis of covariance
[181.
Results
Plasma radiosulfate concentration. In the nor-
mal volunteers, plasma radiosulfate concentration
reached a peak level at 94 8 mm after drinking the
isotope (Fig. 1) and fell thereafter exponentially
with a t1/2 averaging 242 19 mm. Significantly
longer equilibration periods were found in the ure-
mic patients, in whom plasma radiosulfate concen-
trations continued to rise for 161 16 mm (Fig. 1).
In these patients, plasma radiosulfate concentra-
tions fell monoexponentially by 0.5 0.1%/hr after
its peak concentration. This rate is significantly
more rapid than is the physical decay of radio-
sulfate, mandating the use of either a fixed time for
collection of samples or of back extrapolation to a
zero time concentration. The latter method was
chosen because of its practicality.
Clearance and excretion rates of radiosulfate
were also significantly higher (P < 0.001) in normal
volunteers than they were in uremic patients with
partially functioning kidneys (Table 2). Five hours
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after administration of radiosulfate, an average of
37.9 4.6% of the dose was excreted in the urine of
normal volunteers, and 0.8 0.2% was excreted in
the urine of uremic patients.
During hemofiltration, plasma radiosulfate con-
centration fell by 0.4 0. l%/hr, which was not sig-
nificantly different from the fall observed in uremic
patients without hemofiltration. The radiosulfate
concentration of the hemofiltrate was not signifi-
cantly different from that of plasma. Plasma protein
concentration rose consistently in all patients by an
averageof 11.6 2.0%from6.6 0.1 g/lOOml(P<
0.005). Protein concentration of the hemofiltrate av-
eraged 0.2 0.1 g/100 ml.
Radiosulfate space and body weight. Radio-
sulfate space of the normal volunteers (group 1, Fig.
2) ranged between 8,010 and 20,140 ml; and aver-
aged 18.9 0.7% of body weight, in good agree-
ment with previous estimates of ECF volume ob-
tained by oral [6] and i.v. [8-13] administration of
radiosulfate. The relationship between radiosulfate
space and mean body weight was not significantly
different between the two sexes.
Repeated measurements of radiosulfate space in
seven hypertensive patients on a constant sodium
diet (group 2) revealed that the space varied by an
average of 2.6 1.1%; the coefficient of variation in
these measurements was 4.5% (Table 3). Radio-
sulfate space in the hypertensive patients averaged
14,040 1,133 ml or 17.8 1.0% of body weight,
and analysis of covariance showed that the relation-
ship between radiosulfate space and body weight
was not significantly different from that of the nor-
mal volunteers (F = 1.12; P > 0.25).
In uremic patients, radiosulfate space determined
just before dialysis was within normal in 7 and was
clearly expanded in 11 (Fig. 3). Average for the 18
patients (25.3 1.1% of body weight) was signifi-
cantly higher than was that of normal (F = 12.57; P
<0.005). Although none of the patients had clinical
evidence of fluid retention in the control state (that
is, before saline infusion was started), some were
considerably volume-overloaded, and the mean in-
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Time, mm
S ..
Fig. 1. Plasma radiosulfate (35SO) expressed as percent of maxi-
mum concentration, following oral administration of 100 jsCi in
12 normal volunteers (0) and 8 uremic patients (•). Bars repre-
sent SEM.
y= 0.165 X +1.809
r = 0.8587
I I I
25 50 75 100 125
Body wt, kg
Fig. 2.Relationship between extracellular fluid volume (ECF) de-
termined as radiosulfate space and body weight in 12 normal
volunteers of both sexes. Line indicates regression curve:
y = 0.165x + 1.809; r = 0.8587, P < 0.001.









minus measurement 1)Measurement 1 Measurement 2
ml %bodywt ml %bodywt mla %bodywtb
1 16141 20.8 15531 19.9 —610 —0.9
2 11216 14.1 11172 14.2 —44 0.1
3 13209 15.3 14796 16.9 1587 1.6
4 17785 19.3 18505 20.3 720 1.0
5 18872 20.4 18752 20.5 —120 0.1
5 18752 20.5 18823 20.7 71 0.2
6 9915 13.8 9427 13.2 —488 —0.6
6 9427 13.2 9462 13.2 35 0
7 12608 20.7 12470 20.1 —138 —0.6
7 12470 20.1 12456 20.4 —14 0.3
Mean 14040 17,8 14139 17.9 100 0.1
SD 3582 3.3 3699 3.2 632 0.8
a Coefficient of variation (ml): 632 x 100/14,040 = 4.5%.




















25 50 75 100 125
Body weight, kg
Fig. 3. Relationship between ECF determined as radiosulfate
space and body weight in 18 patients with chronic renal failure.
Shaded area represents the range of observations in normal vol-
unteers.
crease in radiosulfate space for the 18 patients aver-
aged 34 6% above normal.
Extracellular fluid volume changes following he-
mofiltration and volume expansion. Following he-
mofiltration, radiosulfate space was reduced by an
average of 1,833 120 ml (Table 4), which was not
significantly different from the volume of hemo-
filtration fluid removed (1,843 91 ml). There was a
significant correlation (y = 1.03x —6.42, r = 0.76; P
< 0.001) between the calculated decrease in ECF
and direct determination of the hemofiltrate vol-
0 Volume loading
S Hemofiltration
0 —2 4 62
Body weight
Fig. 4. Relationship between changes in ECF volume (AECF)
and body weight (Abody wt) in uremic patients during volume
loading (0) and volume depletion by hemofiltration (•). Line
indicates regression curve of all observations: y = l.025x —
69.7; r = 0.9876, P < 0.0001.
ume. Expressed as percent of hemofiltrate, the
changes in ECF ranged between 74 to 126%, in-
dicating an accuracy of more than 70% in detecting
acute changes in ECF by volume depletion. Fur-
thermore, the loss of weight during hemofiltration
was closely paralleled by the fall in ECF (Fig. 4,
Table 4), indicating that virtually all of the hemo-
filtrate was removed from the ECF space. Similar-
ly, a close correlation was found between variation
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ml % body wt
Before hemofiltration 14 71.2 3.6 17493 738 25.1 1.2
After hemofiltration 14 69.5 3.6 15660 726 22.9 1.0
Change 1.7 0.1 1833 120 2.2 0.2
P < 0.001 <0.001 <0.001
Before volume loading 4 77.0 8.8 16405 3227 21.3 3.2
After volume loading 4 81.5 7.9 20975 3169 26.0 3.3
Change 4.5 1.1 4570 1013 4.7 1.5
P < 0.01 < 0.005 <0.005
in determined radiosulfate space and in body weight
during expansion (Fig. 4). Following saline infusion
in four patients, ECF rose by an average of 4,570
1,013 ml, but body weight increased by 4.5 1.1 kg
(Table 4). Repeated measurements of radiosulfate
space during the period of fluid loading showed that
ECF rose in concert with the rise in body weight.
Estimates of fluid gains during volume-loading
ranged between 85 and 132% of the concomitant ris-
es in body weight, indicating an accuracy of mea-
surements of changes of more than 75%. The same
linear relationship between changes in ECF and
body weight was observed whether fluid was re-
moved from the uremic patients by hemofiltration
or added by saline infusion (y = I .03x — 69.7, r =
0.99, P < 0.0001).
Discussion
Body fluid balance is disturbed in many cardio-
vascular and renal diseases, and measurements of
body fluid volumes are essential to the understand-
ing of their pathophysiology. Since radioisotopes
for i.v. injection became practically unavailable, it
has been difficult to find suitable tracers for mea-
surements of ECF. This study shows that oral ad-
ministration of radiosulfate is a good alternative to
the i.v. route of administration, and that reproduc-
ible estimates of sulfate space may be obtained by
this technique both in normal individuals and in ure-
mic patients. It was further shown that oral admin-
istration of radiosulfate may be used for repeated
measurements; and hence, that it may be used to
calculate changes in ECF during manipulations with
body fluid volumes. The technique was purpose-
fully simplified to help its clinical application, and
this was shown not to sacrifice its accuracy.
Three different questions arise from this ap-
proach. The first relates to the choice of radio-
sulfate, the second, to its absorption after oral ad-
ministration, and the third, to its volume of distribu-
tion in pathologic states.
Choice of radiosulfate. In addition to availability
for oral application, radiosulfate was chosen as
tracer to estimate ECF because of its properties as
an extracellular ion. Direct measurements of radio-
sulfate uptake by cells of the whole body are not
available, but the finding that radiosulfate space
both in man and in experimental animals is almost
identical to the distribution volumes of molecules as
different as those of mannitol, thiosulfate [19], and
inulin [8, 11, 19] indicates that cellular inclusion of
sulfate is small. This is also supported by the obser-
vation that radiosulfate spaces of isolated tissues
like heart muscle [20] and skeletal muscle [20—22]
very rapidly reach their maximal values. The larger
volumes of distribution of bromide and chloride are
thought to be due to larger penetration into cells
[20—23] connective tissue [24], and gastrointestinal
fluid [22, 25]. Possible errors in calculation caused
by renal loss and extrarenal metabolism of radio-
sulphate may be corrected by extrapolating back to
zero time concentration [11, 15, 261.
Oral administration of radiosulfate. The most im-
portant objection to the oral administration would
be incomplete absorption, as this would lead to
falsely high values of radiosulfate space. Bauer
showed, however, that in fasting, normal volun-
teers, plasma concentrations of radiosulfate were
almost identical 60 mm after either oral or i.v. ad-
ministration of the isotope [6]. In the present study,
radiosulfate was only administered orally, but the
finding of ECF volumes within the range previous-
ly observed in normal subjects using i.v. injection
[6, 8—13] agrees with his conclusion and suggests
virtually complete absorption. This conclusion is
strengthened by the finding that the radiosulfate ex-
cretion rate after oral administration was similar to
that after i.v. administration [8, 11, 12]. Further-
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more, measurements of radiosulfate space were
highly reproducible, as shown by repeated determi-
nations in the same individuals on constant diets
(Table 3). This was further confirmed by the high
correlation (r = 0.99) with a slope of 1.025 between
changes in body weight induced by volume manipu-
lations and ECF changes determined by the tech-
nique (Fig. 4). That oral absorption of radiosulfate
is not a major source of error in uremic patients was
also supported by the fact that our estimates of ra-
diosulfate space in uremic patients were within the
same range previously defined by i.v. radiosulfate
[14—161. As discussed by Moore et al [27], the ECF
space is not a well-defined anatomical entity for
which an absolute measure exists. Hence, the accu-
racy of a technique for its measurement depends on
concordance with measurements from other labora-
tories, on tests of reproducibility, and on ability to
detect expected changes induced by acute volume
depletion or expansion.
Radiosulfate space in uremic patients. The use of
radiosulfate as an index of ECF in disease requires
that its metabolism or distribution not be altered by
the disease state. This applies to all markers used to
determine ECF. Unfortunately, no direct measure-
ments of possible changes in cellular permeability
for radiosulfate exist. Dow and Irvine [28] have
shown, however, that muscle cells have the same
permeability for inulin and chloride before and 30
hours after nephrectomy, which, if valid also for
sulfate, would imply similar ratio of distribution be-
tween intra- and extracellular fluid compartments in
subjects with normal and impaired renal function.
Some indirect arguments against altered metabo-
lism or distribution can be developed from our
study. First, after equilibration, plasma radiosulfate
concentration fell slowly and predictably in uremic
patients. In agreement with McGrath et al [161 dis-
appearance curves were even found in our patients
without kidneys, suggesting a slow diffusion of ra-
diosulfate. The monoexponential nature of the dis-
appearance curves (Fig. 1) argues, however, against
any large secondary elimination of uneven mixing
of the isotope in uremic patients. Second, the slow
elimination rate of only about 0.5%/hr does not sug-
gest enhanced metabolism. Finally, the usefulness
of the technique for measurements of ECF in ure-
mic patients as well as in normal subjects is demon-
strated, in our opinion, by the high correlation be-
tween calculated changes in radiosulfate space and
body weight during hemofiltration and acute vol-
ume expansion (Fig. 4).
The longer equilibration period needed for pa-
tients with end-stage renal disease does not influ-
ence the calculation of radiosulfate space because
of back-extrapolation of plasma concentration to
zero time. Since the equilibration period after oral
administration of radiosulfate is longer in uremic
patients than it is in normal subjects, it is more con-
venient to give the dose at night and collect the
blood samples the following morning. A technical
advantage to be gained from the slow and constant
elimination of radiosulfate is that sulfate space may
be determined in uremic patients from one blood
sample obtained after equilibration has occurred.
Furthermore, in the present calculations of changes
in ECF during hemofiltration where the loss of ra-
diosulfate in the hemofiltrate could be calculated di-
rectly, it was not necessary to await a new equili-
bration period following a second dose of radio-
sulfate. Since the extrarenal loss of radiosulfate
occurs at a fixed rate for a long period of time, de-
viations from the decay of 0.5%/hr might also in-
dicate expansion or contraction of the ECF space
which do not alter the body stores of radiosulfate.
It has been suggested that part of the fluid re-
moved by hemodialysis might be replaced by intra-
cellular fluid, and hence that hemodialysis could
reduce that volume [29]. This seems not to occur
during hemofiltration. A shift in fluid from the in-
tracellular to the extracellular fluid space would
dilute the radiosulfate remaining in the extracellular
fluid and thereby reduce plasma radiosulfate con-
centration. The observation, however, that the con-
centration of radiosulfate in the hemofiltrate was
the same as in plasma, and that plasma radiosulfate
concentration fell at a similar rate whether hemo-
filtration was performed or not, show that the he-
mofiltrate was removed almost entirely from the
ECF space alone. This contention is supported by
the close agreement during hemofiltration of
changes in sulfate space with simultaneous changes
in body weight (Table 4) and with amount of fluid
removed. A rise in plasma protein concentration of
11.6% also corresponds well with a mean fall in
ECF of 10.5% (Table 4), confirming the previous
observation that hemofiltration removes fluid in ap-
proximately equal proportion from plasma volume
and interstitial fluid space [30].
Of 18 uremic patients 11 had radiosulfate vol-
umes above the upper limit as defined in the
group of normal volunteers (Fig. 3). On an aver-
age, radiosulfate space was expanded by one third
above normal, equivalent to about 4,300 ml/1 .73 m2.
Yet there were no signs of edema of fluid retention
in any of the patients, which is in agreement with
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the clinical impression that edema usually does not
become apparent until the overload of fluid exceeds
10% ofbody weight; in our patients, the calculated
fluid retention amounted to about 6% of body
weight. Thus, despite apparently "adequate" he-
modialysis, more than three fifths of the patients
were chronically overloaded with fluid. During he-
mofiltration, some 2,000 ml of fluid was removed,
but as this amounted to only about half the excess
fluid, seven of the uremic patients still remained
overhydrated after the treatment. Similar degrees of
volume expansion without clinical signs of edema
or fluid retention have previously been found in re-
nal patients when different tracers for measure-
ments of ECF were used [3, 31] and in patients with
heart failure 19, 11, 1411.
From these observations it is apparent that full
control of the fluid balance of uremic patients may
sometimes rely on direct ECF measurements. In
that regard, the technique reported can be a useful
tool; it can also provide reproducible and accurate
determinations of ECF for subjects with either nor-
mal or impaired renal function.
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